Fasoracetam

Investigational Nootropic

Experimental racetam studied in small precision-medicine ADHD trials and earlier development programs. Evidence is insufficient to establish broad efficacy, routine dosing, long-term safety, or a validated PK model.

Pharmacokinetic model

A route-level PK model for fasoracetam is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Investigational Nootropic
Suggested cadence: once daily

Research behind this entry

Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, Chiavacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kumar B, Potts J, Davis J, Malatack J, Slattery E, Moorthy G, Zuppa A, Weller A, Byrne E, Li YR, Kraft WK, Hakonarson H · Nature Communications, 2018 DOI
Small genotype-selected adolescent study reported symptom changes during fasoracetam exposure. Its open-label, selected-cohort design does not establish general ADHD efficacy or consumer nootropic benefit.
Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD Nageye F, Cortese S · Expert Review of Neurotherapeutics, 2019 DOI
Systematic review placed fasoracetam among experimental non-stimulant candidates and emphasized the limited evidence base for novel ADHD compounds.

2 published studies referenced in the app, each with a plain-language summary.